ArticleJournal of translational medicine2025
Mitochondrial transplantation attenuates alveolar epithelial cell dysfunction and reduces disruption of tight junction proteins to alleviate lung ischaemia-reperfusion injury.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hypoxia-preconditioned mitochondrial transplantation multidirectionally modulates Schwann cell functions to repair peripheral nerve injury in rats.Journal of orthopaedic translation · 2026Article
- Evolution in lung IRI cell death research: a 20-year global bibliometric study (2005-2024).Annals of medicine and surgery (2012) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study aims to investigate the therapeutic effect of exogenous mitochondrial transplantation (MT) on lung ischemia-reperfusion injury (LI/RI), and analyze the impact of MT on alveolar epithelial cell function and the ultrastructure of the alveolar epithelial barrier.
methodsTo simulate the pathological process of LI/RI, we established a hypoxia-reoxygenation model using mouse alveolar epithelial cells (MLE-12 cells) and a LI/RI model in male C57BL/6 mice. Based on these models, we further evaluated the therapeutic effect of mouse liver-derived mitochondrial transplantation on LI/RI.
resultsThe results of this study showed that MT exhibits significant therapeutic potential in LI/RI. Both in vitro and in vivo experiments confirmed that MT can significantly ameliorate lung tissue injury by reducing oxidative stress levels, alleviating inflammatory responses, and decreasing cell apoptosis and necrosis. Meanwhile, MT is capable of alleviating alveolar epithelial cell dysfunction, reducing the disruption of tight junction proteins, and preserving the integrity of the alveolar epithelial barrier, thereby mitigating LI/RI.
conclusionOur study confirmed in the LI/RI model that MT therapy can repair the alveolar barrier structural damage caused by ischemia-reperfusion by targeting the regulation of the expression levels of tight junction proteins in alveolar epithelial cells. This finding provides a new perspective for clarifying the target of action through which MT therapy protects alveolar barrier function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.